1. Academic Validation
  2. Silencing SPP1 in M2 macrophages inhibits the progression of castration-resistant prostate cancer via the MMP9/TGFβ1 axis

Silencing SPP1 in M2 macrophages inhibits the progression of castration-resistant prostate cancer via the MMP9/TGFβ1 axis

  • Transl Androl Urol. 2024 Jul 31;13(7):1239-1255. doi: 10.21037/tau-24-127.
Saipeng Chen # 1 Bingqian Deng # 2 Fuhan Zhao # 1 Hang You 3 Youxin Liu 1 Langlang Xie 2 Guojing Song 1 Zhansong Zhou 1 Gang Huang 2 Wenhao Shen 1
Affiliations

Affiliations

  • 1 Department of Urology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
  • 2 Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Army Medical University (Third Military Medical University), Chongqing, China.
  • 3 Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
  • # Contributed equally.
Abstract

Background: M2 macrophages can promote the progression of castration-resistant prostate Cancer (CRPC), but the specific mechanism is still unclear. Therefore, we are preliminarily exploring the molecular mechanism by which M2 macrophages regulate the progression of CRPC.

Methods: The genes positively correlated with CRPC and with the most significant differences in the GEO32269 dataset were obtained. Database and immunofluorescence experiments were used to validate the localization of secreted phosphoprotein 1 (SPP1) in localized prostate Cancer (PCa), hormone-sensitive prostate Cancer (HSPC), and CRPC tumor tissues. The function of SPP1 in M2 macrophages was verified through cell scratch, Transwell, and an orthotopic PCa model. PCa database and Western blot were used to verify the relationship between SPP1 and matrix metallopeptidase 9 (MMP9), as well as the ability of MMP9 in M2 macrophages to promote epithelial-mesenchymal transition (EMT) in PCa cells.

Results: The primary localization of SPP1 in prostate and CRPC tissues is in macrophages. Silencing SPP1 expression in M2 macrophages promotes their polarization towards the M1 phenotype and significantly inhibits the malignant progression of PCa in vitro and in vivo. SPP1 promotes the expression of MMP9 through the PI3K/Akt signaling pathway in M2 macrophages. Furthermore, MMP9 enhances the EMT and migratory capabilities of PC3 cells by activating the TGFβ signaling pathway.

Conclusions: We have found that the high expression of SPP1 in M2 macrophages promotes the progression of CRPC through cell-cell interactions. These findings can contribute to the development of novel therapeutic approaches for combating this deadly disease.

Keywords

Castration-resistant prostate cancer (CRPC); epithelial-mesenchymal transition (EMT); matrix metallopeptidase 9 (MMP9); secreted phosphoprotein 1 (SPP1); transforming growth factor beta signaling pathway (TGFβ signaling pathway).

Figures
Products
Inhibitors & Agonists
Other Products